Physiologas Selected for Tokyo Metropolitan Government's Advanced Medical Device Acceleration Project (AMDAP)

Physiologas Technologies Inc. (Headquarters: Sagamihara City, Kanagawa Prefecture, Representative Director: Kazuyoshi Miyawaki, hereinafter referred to as "the Company") is pleased to announce that it has been selected as a subsidized project recipient (up to 6 years, maximum 600 million yen) for the Advanced Medical Device Acceleration Project (AMDAP), which supports the development of advanced medical devices by venture companies and SMEs in Tokyo.

■ Business Plan Name: Development of a home hemodialysis device that does not use tap water

■ Business Plan Overview:

・Hemodialysis treatment requiring hospital visits places a significant burden on patients, both in terms of time and physical strain. Current home hemodialysis devices are large due to the need for water supply and drainage facilities, and are difficult to operate as they are designed for medical professionals.

・By employing technology that recirculates dialysate within the system, we will develop a compact home hemodialysis device that does not require water supply and drainage facilities and can be easily operated by patients at home.

■ Maximum Grant Amount: Up to 6 years, maximum 600 million yen

Please refer to the link below for the announcement regarding the selection for the AMDAP subsidy program by the Tokyo Metropolitan Government.

https://www.metro.tokyo.lg.jp/information/press/2026/03/2026032625

https://amdap.metro.tokyo.lg.jp/

With this selection, we will accelerate the social implementation of home hemodialysis to improve the quality of life for patients with end-stage renal failure and their families.

About the Advanced Medical Device Acceleration Project (AMDAP) for Supporting the Development of Advanced Medical Devices by Venture Companies and SMEs in Tokyo

The medical device industry is expected to achieve sustained growth in the future, not only domestically but also globally. However, looking at the market structure, while domestic manufacturers have a certain strength in diagnostic equipment, which accounts for half of the market in terms of value, the import ratio from overseas manufacturers, mainly in Europe and the United States, is high for therapeutic equipment, which is expected to grow more rapidly. This means that Japan's strength in reliable manufacturing is not being fully utilized. On the other hand, Tokyo has a concentration of specialized human resources in areas such as clinical evaluation, regulations, medical insurance systems, as well as business and finance, indicating high potential for medical device development.

This project provides intensive support for the development and commercialization of medical devices that contribute to the advancement of medicine, by providing guidance and advice from experts in various fields concentrated in Tokyo to the business plans of venture companies and SMEs with a high development mindset in the medical device industry, where they are at a disadvantage compared to European and American manufacturers. The most outstanding business plans will receive research and development subsidies, including clinical trial costs (up to 3 years per phase, up to 300 million yen per phase, subsidy rate within 2/3, for up to two phases (up to 6 years, maximum 600 million yen, subsidy rate within 2/3)).

Through these initiatives, we aim to foster the development of advanced medical devices.